We can’t show the full text here under this license. Use the link below to read it at the source.
Sodium–glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score‐matched model analysis in Japan
Lowering blood pressure with SGLT2 inhibitors may improve kidney outcomes in type 2 diabetes patients with chronic kidney disease in Japan
AI simplified
Abstract
Patients with a reduction (ΔMAP) of ≤-4 mmHg experienced a lower incidence of adverse renal outcomes compared to those with ΔMAP ≥-4 mmHg.
- A total of 624 Japanese type 2 diabetes mellitus patients with chronic kidney disease were analyzed for this study.
- Patients were grouped based on the degree of blood pressure reduction after SGLT2 inhibitor treatment.
- Those with ΔMAP ≤-4 mmHg had a significantly lower incidence of composite renal outcomes (5.8% vs 15.6%, P = 0.003).
- No significant differences were observed in estimated glomerular filtration rates between the two groups.
- Patients with ΔMAP ≤-4 mmHg showed significantly larger reductions in urine albumin-to-creatinine ratio (P = 0.005).
AI simplified
Key numbers
5.8%
Lower Incidence of Renal Outcomes
Incidence of renal outcomes in patients with Δ ≤−4 mmHg
15.6%
Higher Incidence of Renal Outcomes
Incidence of renal outcomes in patients with Δ >−4 mmHg